Denali Therapeutics (DNLI) Long-Term Deferred Tax (2018)
Denali Therapeutics (DNLI) posted quarterly Long-Term Deferred Tax of $23.5 million for Q1 2018.
Powered by 
Analysis
Denali Therapeutics (DNLI) Long-Term Deferred Tax (2018) Analysis & Trends
Denali Therapeutics (DNLI) has reported Long-Term Deferred Tax for 1 consecutive years, with $23.5 million the latest figure, recorded in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 4.18 Bn | 4.18 Bn | 3.51 Mn |